Article Text

Download PDFPDF
CASE REPORT
Use of propranolol in a remote region of rural Guatemala to treat a large facial infantile haemangioma
  1. Vera Goldberg1,
  2. Boris Martinez2,
  3. Katia Cnop2,
  4. Peter Rohloff3
  1. 1Harvard Medical School, Boston, Massachusetts, USA
  2. 2Wuqu' Kawoq, Santiago Sacatepéquez, Guatemala
  3. 3Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA
  1. Correspondence to Dr Peter Rohloff, prohloff{at}partners.org

Summary

We present a female infant with a right-sided facial and neck haemangioma, from a remote, resource-poor community in rural Guatemala. She received first-line treatment, propranolol, with marked reduction in tumour size and erythema. Treatment was stopped after 35 weeks due to recurrent diarrhoea and sustained weight loss. Propranolol can be used to safely treat infants with haemangiomas in remote, rural communities if there is adequate follow-up, education and communication. Periocular haemangiomas should be treated promptly to avoid visual impairment. Infants with large facial haemangiomas should be screened for Posterior fossa anomalies, Hemangioma, Arterial anomalies, Cardiac anomalies, and Eye anomalies (PHACE) syndrome, and specialists should be involved. The case also highlights the difficulty of providing treatment for a complex illness when basic health needs, such as food security and water sanitation, are limited.

  • Global Health
  • Hemangioma
  • Congenital disorders
  • Pharmacology and therapeutics

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors VG provided clinical care and drafted the manuscript.

    BM provided clinical care and critically revised the manuscript.

    KC critically revised the manuscript.

    PR critically revised the manuscript.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.